Clinical Trials Directory

Trials / Completed

CompletedNCT05072938

Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis

A Multi-center, Open-label, Randomized, Phase IV Clinical Trial to Compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
260 (actual)
Sponsor
Daewoong Pharmaceutical Co. LTD. · Industry
Sex
All
Age
19 Years – 74 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy with Nizatidine Monotherapy in Patients with Gastritis

Detailed description

The purpose of this study is to compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy with Nizatidine Monotherapy in Patients with Gastritis. Anticipated result is to prove superiority of Rebamipide/Nizatidine combination therapy at 2 weeks compared to Nizatidine Monotherapy.

Conditions

Interventions

TypeNameDescription
DRUGMucotra SR Tablet 150mgRebamipide/Nizatidine Combination Therapy
DRUGAxid Capsule 150mgNizatidine Monotherapy

Timeline

Start date
2021-09-30
Primary completion
2022-12-15
Completion
2022-12-15
First posted
2021-10-11
Last updated
2024-07-01

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT05072938. Inclusion in this directory is not an endorsement.

Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastrit (NCT05072938) · Clinical Trials Directory